Novartis 2Q net slips as generic drug competition hits sales

GENEVA (AP) — Swiss pharmaceuticals company Novartis says net profit from continuing operations fell 3 percent in the second quarter, largely because of new generic competition for its top cancer drug even as it expressed high hopes for a psoriasis drug that has turned out to be one of its best product launches ever.